Telcon RF Pharmaceutical’s pharmaceutical business has continued its stable growth trajectory this year, accelerating efforts to strengthen its business fundamentals by expanding production infrastructure and developing new pipelines in parallel.
According to Telcon RF Pharmaceutical on December 29, the pharmaceutical division’s sales are estimated to have grown by more than 30% compared to the previous year. The steady expansion of demand for the gastrointestinal protectant product line (Algicel Liquid, active ingredient sodium alginate) has been driving performance growth. The company’s market dominance for its core products is also gradually strengthening, and sales for the pharmaceutical division are projected to exceed 35 billion won next year.
In line with this growth, the company is also investing in production and logistics infrastructure. To prepare for increasing order volumes and expanding demand, Telcon RF Pharmaceutical is progressively advancing production process optimization and logistics automation. The company is currently installing palletizers to reduce the workload on production staff and is planning to build a new high-rack warehouse with a capacity of 2,000 cells to improve convenience and efficiency for contract manufacturers’ product inbound and outbound operations.
This infrastructure expansion is also intended to proactively address the pharmaceutical supply instability and shortage issues that have recently become a concern across the industry. The strategy is to establish a stable production and supply system, enhance trust with business partners, and reinforce the foundation for mid- to long-term growth.
The development of new pipelines is also gaining momentum. The company is focusing on developing specialized product lines, such as treatments for hyperkalemia in dialysis patients, targeting the chronic disease treatment market that has gained attention during the COVID-19 pandemic. Product development and marketing strategies are being considered simultaneously, leveraging networks of medical professionals and associations such as the Nephrology Society and Hospital Association.
This is part of a mid- to long-term strategy to reduce dependence on specific products and diversify the product portfolio. The company aims to improve treatment accessibility for chronic disease patient groups and establish a structure that generates stable, recurring demand.
A Telcon RF Pharmaceutical representative stated, “Alongside the stable growth of our existing core products, we are simultaneously pursuing infrastructure expansion and new treatment development,” adding, “We plan to further strengthen our growth foundation so that the pharmaceutical division can continue to achieve double-digit growth next year compared to this year.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
